Inhibitex continues higher, sets another trade catalyst in play |
![]() |
![]() |
By M.E.Garza | |
Tuesday, 29 November 2011 11:26 | |
![]() On Friday, October 7th, when shares were trading at $2.96 we told our premium scubscribers that shares were starting to climbing quietly. The stock had battled back from an insider sale scare, and despite the fact that nearly 3 million shares were short, pressure to cover was mounting as bulls continued to push the stock price higher. By early November, shares continued to climb significantly- just as the company was set to announce its financial results for the third quarter and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189. The firm reported today that, subject to regulatory review, it plans to further expand ongoing studies of its most advanced hepatitis C drug (INX-189). It wants to test bigger doses and try one regimen that does not include pegylated interferon, an IV drug that is associated with severe side effects. The Company anticipates that the Phase 1b extension trial will be completed in the first quarter of 2012.That now becomes yet another forward looking news catlyst for biotech traders, so shares should continue trading actively for some time to come despite the fact that we may see some profit taking in the days ahead. Smart money still loves Inhibitex and we would not be surprised to see more institutional buying when the stock starts forming a base for its next leg up. Inhibitex's pipeline addresses significant viral and bacterial infections, including herpes zoster (shingles), chronic hepatitis C, and S. aureus infections. The company's product pipeline includes: FV-100, a bicyclic nucleoside analogue in development for the treatment of herpes zoster (shingles), Aurexis®, a humanized monoclonal antibody with a high affinity and specificity to clumping factor A (ClfA), which is expressed by virtually all strains of S. aureus and INX-189, indicated for Hepatitis C. Hepatitis C is a viral disease that leads to swelling (inflammation) of the liver. Most people who were recently infected with hepatitis C do not have symptoms. About 10% have jaundice that gets better.Of people who get infected with HCV, most develop chronic HCV infection. Usually there are no symptoms. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |